Table 1. Patients information.

A. General characteristics of the groups
Groups	No. of patients	Age [years]Median (IQR)	Hb [g/dl]Median (IQR)	Serum Epo [mU/ml]Median (IQR)	O/P ratioMean±SD	Epo mRNA [copies/10 kCPB]Median (IQR)	EpoR mRNA [copies/10 kCPB]Median (IQR)	Survival [months]Median
Donor	38	50.5 (34.0–59.8)	15.1 (13.9–16.3) n = 9	12.7 (8.7–13.3) n = 9	1.01±0.12	20 (13–25) n = 29	174 (124–281) n = 29
Male	25	46.0 (30.5–60.5)	15.9 (14.9–16.3) n = 6	12.9 (11.3–13.7) n = 6	1.06±0.10	16 (10–25) n = 19	148 (104–255) n = 19)
Female	13	52.0 (43.5–60.5)	13.8 (13.5–13.9) n = 3	9.2 (8.1–12.7) n = 3	0.90±0.08	22 (15–26) n = 10	240 (152–544) n = 10)
CP	42	47.0 (38.0–54.0)	12.9 (12.0–14.2) n = 42	12.0 (8.9–18.8) n = 13	0.99±0.23	7 (2–13) n = 29	351 (219–533) n = 29)
Male	31	50.0 (37.0–56.0)	13.6 (12.3–14.5) n = 31	11.3 (8.0–15.1) n = 10	0.92±0.17	9 (2–16) n = 21	355 (219–533) n = 21)
Female	11	44.0 (40.0–48.0)	11.8 (10.8–12.9) n = 11	18.2 (13.7–74.4) n = 3	1.25±0.25	5 (2–9) n = 8)	322 (218–538) n = 8)
PDAC	150	65.0 (56.0–70.3)	13.0 (11.9–13.9) n = 150	9.8 (5.6–15.2) n = 87	0.85+0.24	1 (0–2) n = 104	176 (94–302) n = 104)	18.0
Male	80	63.5 (56.0–70.8)	13.7 (12.0–14.5) n = 80	8.5 (5.3–15.5) n = 42	0.87±0.25	0 (0–4) n = 60	149 (95–281) n = 60)	17.0
Female	70	65.0 (57.8–70.3)	12.6 (11.8–13.5) n = 70	10.0 (6.0–15.3) n = 45	0.84±0.24	1 (0–2) n = 44	183 (94–418) n = 44)	18.5